ID: ALA5196781

Max Phase: Preclinical

Molecular Formula: C22H23N5O3

Molecular Weight: 405.46

Representations

Canonical SMILES:  COc1cc(Nc2nc(CN)cc3c(-c4ccccc4)n[nH]c23)cc(OC)c1OC

Standard InChI:  InChI=1S/C22H23N5O3/c1-28-17-10-14(11-18(29-2)21(17)30-3)24-22-20-16(9-15(12-23)25-22)19(26-27-20)13-7-5-4-6-8-13/h4-11H,12,23H2,1-3H3,(H,24,25)(H,26,27)

Standard InChI Key:  MUOWIESEBCJGBI-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 405.46

Molecular Weight (Monoisotopic): 405.1801

AlogP: 3.85

#Rotatable Bonds: 7

Polar Surface Area: 107.31

Molecular Species: NEUTRAL

HBA: 7

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 10.44

CX Basic pKa: 8.35

CX LogP: 2.88

CX LogD: 1.88

Aromatic Rings: 4

Heavy Atoms: 30

QED Weighted: 0.43

Np Likeness Score: -0.72

References

1. Stampelou M, Suchankova A, Tzortzini E, Dhingra L, Barkan K, Lougiakis N, Marakos P, Pouli N, Ladds G, Kolocouris A..  (2022)  Dual A1/A3 Adenosine Receptor Antagonists: Binding Kinetics and Structure-Activity Relationship Studies Using Mutagenesis and Alchemical Binding Free Energy Calculations.,  65  (19.0): [PMID:36173355] [10.1021/acs.jmedchem.2c01123]

Source

Source(1):

• Scientific Literature